New techniques have been developed as a result of the focus on lowering lead time, sample consumption, assessment costs, and constraints associated with certain technologies. The growing use of technology provides a chance for medium- and small-scale labs to expand their product lines and compete with major industry players, as these advancements offer benefits including enhanced sensitivity, accurate results, durability, multi-contaminant, and non-targeted monitoring with short turnaround time. For instance, in August 2021, Eurofins strengthened its global position in cosmetics and personal care products testing and clinical services and grew its position in dermatology drug testing in order to diversify its clinical examination footprint in dermatology, for medicinal products, and medical devices.